High VEGF/VEGFR-2 expression correlates with poor outcomes in EGFR-mutant NSCLC.Combining VEGF inhibitors such as bevacizumab or ramucirumab with EGFR-TKIs significantly improves PFS. Anlotinib has shown improved survival outcomes in TKI-resistant patients when combined with immune checkpoint inhibitors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.